Core Viewpoint - Vigen International Holdings Limited has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International as its sole sponsor, focusing on innovative treatments for kidney and blood diseases [1] Company Overview - Vigen International is a leading comprehensive pharmaceutical company in China, specializing in the treatment of kidney and blood diseases, with capabilities in drug development, production, and commercialization [1] - The company aims to address significant unmet clinical needs in the treatment of kidney and blood diseases and other major diseases through innovative and valuable therapeutic solutions [1] Product Portfolio - Vigen has developed a diverse and differentiated product portfolio that covers a wide range of kidney and blood diseases, extending to respiratory and skin diseases [1] - According to Zhi Shi Consulting, as of the last practicable date, Vigen's product portfolio includes six kidney drugs, making it the Chinese pharmaceutical company with the highest number of commercialized original drugs for kidney disease [1]